Nektar Therapeutics
NKTR
$56.23
-$0.39-0.69%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.83% | -25.25% | -51.13% | -52.42% | -51.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.83% | -25.25% | -51.13% | -52.42% | -51.66% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 3.83% | 2.87% | -40.12% | -18.72% | -20.18% |
| SG&A Expenses | -44.80% | -34.72% | -15.23% | -16.76% | 20.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.41% | -24.06% | -25.85% | -21.70% | -2.26% |
| Operating Income | 13.77% | 22.66% | 8.07% | 1.92% | -28.78% |
| Income Before Tax | 11.78% | -614.82% | 4.03% | 20.14% | -37.99% |
| Income Tax Expenses | 23.08% | 111.97% | -466.67% | -508.70% | 248.57% |
| Earnings from Continuing Operations | 11.75% | -596.89% | 4.14% | 20.57% | -38.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.75% | -596.89% | 4.14% | 20.57% | -38.26% |
| EBIT | 13.77% | 22.66% | 8.07% | 1.92% | -28.78% |
| EBITDA | 13.27% | 22.38% | 5.91% | -1.55% | -33.78% |
| EPS Basic | 49.83% | -442.31% | 29.42% | 21.50% | -27.64% |
| Normalized Basic EPS | 50.58% | 40.91% | 29.53% | -4.66% | -30.42% |
| EPS Diluted | 49.83% | -448.62% | 29.42% | 21.50% | -27.64% |
| Normalized Diluted EPS | 50.58% | 39.82% | 29.53% | -4.66% | -30.42% |
| Average Basic Shares Outstanding | 75.89% | 45.16% | 35.82% | 1.19% | 8.32% |
| Average Diluted Shares Outstanding | 75.89% | 42.54% | 35.82% | 1.19% | 8.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |